Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Summary
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Detailed description
This research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to: * Better understand causes of lung cancer in individuals 45 years old and younger, which is a rare disease * Better estimate lung cancer risks and potential risk factors for lung cancer in individuals 45 years old and younger * Examine tumor (somatic) or normal (germline) genetic changes that may be shared among young lung cancer patients * Improve opportunities for screening and treatment of lung cancer in individuals 45 years old and younger Study procedures will include: * Collecting information from participants' medical record and two (2) short questionnaires * Collecting blood and/or saliva samples * Collecting tumor tissue samples (optional) It is expected that about 500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent.
Arms & interventions
- GeneticData and Specimen Collection
* Provide research team access to relevant medical records * Answer two (2) short questionnaires at time of consent * Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample * Consider consenting to other optional parts of the research such as: * Providing additional blood or tissue samples in the future (optional) * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)
Outcome measures
Primary
Repository of specimens and data
Prospective registry of young lung cancer specimens for exploratory tumor and germline genomics, transcriptomics/proteomics, and future biomarker study.
Time frame: 5 years or study closure
Secondary
Number of patients with targetable somatic alterations in known oncogenic driver genes
Time frame: 5 years or study closure
Number of patients with predicted oncogenic alterations in unknown driver genes
Time frame: 5 years or study closure
Number of patients with pathogenic or likely pathogenic germline alterations in known cancer predisposition genes
Time frame: 5 years or study closure
Eligibility criteria
Study locations (4)
Massachusetts General Hospital
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115